The content is available as a PDF (93.8 KB).
Bibliographie/References
- 1.Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg Infect Dis. 1999;5(5):659–71. doi: 10.3201/eid0505.990507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998;351(9101):467–71. doi: 10.1016/S0140-6736(98)01182-9. [DOI] [PubMed] [Google Scholar]
- 3.Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease. J Infect Dis. 1999;180(2):505–8. doi: 10.1086/314903. [DOI] [PubMed] [Google Scholar]
- 4.de Claas EC, van Jong JC, Beek R, et al. Human influenza virus A/Hong/Kong/156/97 (H5N1) infection. Vaccine. 1998;16(9-10):977–78. doi: 10.1016/S0264-410X(98)00005-X. [DOI] [PubMed] [Google Scholar]
- 5.Snacken R, Kendal AP, Haahein LR, Wood JM. The next influenza pandemic: Lessons from Hong Kong, 1997. Emerg Infect Dis. 1999;5(2):195–203. doi: 10.3201/eid0502.990202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Buck P, Herman S, Scott C, et al. Influenza in Canada 1997–1998 season. Can Commun Dis Rep. 1998;24(1):169–76. [PubMed] [Google Scholar]
- 7.Hampson AW, Cox NJ. Global surveillance for pandemic influenza: Are we prepared? In: Brown LE, Hampson AW, Wester RG, editors. Options for the Control of Influenza III. Amsterdam, the Netherlands: Elsevier Science Publishers; 1996. pp. 50–59. [Google Scholar]
- 8.Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet. 1999;354(9182):916–17. doi: 10.1016/S0140-6736(99)03311-5. [DOI] [PubMed] [Google Scholar]
- 9.Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis. 1999;179(5):1132–38. doi: 10.1086/314713. [DOI] [PubMed] [Google Scholar]
- 10.Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338(20):1405–12. doi: 10.1056/NEJM199805143382002. [DOI] [PubMed] [Google Scholar]
- 11.National Advisory Committee on Immunization. Statement on influenza vaccine for the 1999–2000 season. Can Commun Dis Rep. 1999;25(ACS-2):1–16. [PubMed] [Google Scholar]
- 12.Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180(2):254–61. doi: 10.1086/314904. [DOI] [PubMed] [Google Scholar]
- 13.The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352(9144):1877–81. doi: 10.1016/S0140-6736(98)10190-3. [DOI] [PubMed] [Google Scholar]
- 14.Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA. 1999;282:31–35. doi: 10.1001/jama.282.1.31. [DOI] [PubMed] [Google Scholar]